These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3086534)

  • 1. [An evaluation of substrate-labeled fluorescent immunoassay (SLFIA method) by using pharmacokinetic parameters of valproic acid].
    Johno I; Nakamura T; Hasegawa M; Maeda M; Ogura Y; Kitazawa S
    Yakugaku Zasshi; 1986 Feb; 106(2):169-75. PubMed ID: 3086534
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of blood concentration of valproic acid--a comparative study of methods.
    Noda H; Eto S; Minemoto M
    J UOEH; 1985 Mar; 7(1):89-94. PubMed ID: 3920742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state kinetics of valproic acid in epileptic patients.
    Bruni J; Wilder BJ; Willmore LJ; Perchalski RJ; Villarreal HJ
    Clin Pharmacol Ther; 1978 Sep; 24(3):324-32. PubMed ID: 357068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total and free valproic acid: plasma level/dose ratio in monotherapy.
    Abadín JA; Durán JA; Sánchez A; Serrano JS
    Methods Find Exp Clin Pharmacol; 1991 Apr; 13(3):221-5. PubMed ID: 2051846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of serum phenytoin determination by the substrate-labeled fluorescent immunoassay with gas chromatography, liquid chromatography, radioimmunoassay and "EMIT".
    Wong RC; George R; Yeung R; Burd JF
    Clin Chim Acta; 1980 Jan; 100(1):65-9. PubMed ID: 6985851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.
    Cook AM; Zafar MS; Mathias S; Stewart AM; Albuja AC; Bensalem-Owen M; Kapoor S; Baumann RJ
    CNS Drugs; 2016 Jan; 30(1):71-7. PubMed ID: 26715390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy.
    Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yamaguchi T; Fujimura A
    Am J Health Syst Pharm; 2002 May; 59(9):835-40. PubMed ID: 12004461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy.
    Juárez-Olguín H; Lugo-Goytia G; Flores-Murrieta F; Ruiz-García M; Lares Asseff I; Flores Pérez J
    Rev Invest Clin; 2010; 62(6):516-23. PubMed ID: 21416779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct single-reagent fluorescence polarisation immunoassay for valproic acid in serum.
    Sidki AM; Staley K; Boyes H; Landon J; Williams AH
    J Clin Chem Clin Biochem; 1988 Feb; 26(2):69-74. PubMed ID: 3130457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
    Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
    Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified enzyme-multiplied immunoassay technique valproic acid test kit.
    Meatherall R; Krahn J
    Ther Drug Monit; 1995 Feb; 17(1):104-5. PubMed ID: 7725370
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
    Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
    J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose model for predicting steady-state valproic acid serum concentrations in seizure patients.
    Pugh CB; Garnett WR; Poynor WJ; Pellock JM
    Clin Pharm; 1984; 3(6):643-9. PubMed ID: 6439455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin.
    Miles MV; Snead OC; Thorn MD
    Clin Pharm; 1988 Sep; 7(9):688-93. PubMed ID: 3149223
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites.
    Dupuis RE; Lichtman SN; Pollack GM
    Drug Saf; 1990; 5(1):65-71. PubMed ID: 2106903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Problems of therapeutic service in valproate therapy].
    Köhler E; Quednow B; Walther H
    Z Arztl Fortbild (Jena); 1980 Aug; 74(15):694-7. PubMed ID: 6777996
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors modifying valproate plasma level/dose ratio: age, sex, dose and plasma level.
    Sánchez A; Durán JA; Abadín JA
    Methods Find Exp Clin Pharmacol; 1989 Sep; 11(9):583-6. PubMed ID: 2511386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Valproic acid].
    Kohda Y
    Nihon Rinsho; 1995 Feb; 53 Su Pt 1():918-20. PubMed ID: 8753587
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlations between UGT2B7∗2 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients.
    Zhang H; Zhang W; Li Y; Yan J; Zhang J; Wang B
    Brain Dev; 2018 Feb; 40(2):100-106. PubMed ID: 28958730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.